Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:7 Issue:9 Number:17 ISSN#:2564-2537
RCT
ACE Report #10352
Ace Report Cover Cannabis

Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects


How to Cite

OrthoEvidence. Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects. ACE Report. 2018;7(9):17. Available from: https://myorthoevidence.com/AceReport/Report/10352

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

Clin Ther. 2007 Sep;29(9):2068-79

Contributing Authors: TJ Nurmikko DJ Rog CA Young

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Sixty-six patients from the UK with multiple sclerosis (MS) were enrolled in an initial 5-week, placebo-controlled RCT investigating the use of an oral-mucosal THC/CBD spray (Sativex). This study is an uncontrolled, open-label extension of the initial RCT, where all patients completing the initial RCT (n=64) were eligible to continue on the THC/CBD oral spray, and followed for 2-years. Sixty-three...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.